Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males

British Journal of Clinical Pharmacology

Volumn 81, Issue 4, 2016, Pages 613-620

  Smits, Mark M ^a   Muskiet, Marcel H A ^a   Tonneijck, Lennart ^a   Hoekstra, Trynke ^b,c   Kramer, Mark H H ^a   Diamant, Michaela ^a   Van Raalte, Daniël H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

GLP 1 receptor agonist; haemodynamics; heart rate; sympathetic nervous system activity

Indexed keywords

EXENDIN 4; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G) METHYLARGININE; TRIACYLGLYCEROL; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; LIPID; PEPTIDE; VENOM;

ADRENERGIC SYSTEM; ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG SAFETY; ELEVATED BLOOD PRESSURE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART RATE; HEART RATE VARIABILITY; HUMAN; MALE; MEAN ARTERIAL PRESSURE; OBESITY; OPEN STUDY; PHOTOELECTRIC PLETHYSMOGRAPHY; PRIORITY JOURNAL; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR RESISTANCE; VASODILATATION; AGONISTS; ANALYSIS; BLOOD; BODY MASS; CLINICAL TRIAL; DRUG EFFECTS; NORMAL HUMAN; YOUNG ADULT;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CROSS-OVER STUDIES; GLUCAGON-LIKE PEPTIDE 1; HEALTHY VOLUNTEERS; HEART RATE; HUMANS; LIPIDS; MALE; OVERWEIGHT; PEPTIDES; SYMPATHETIC NERVOUS SYSTEM; VASCULAR RESISTANCE; VENOMS; YOUNG ADULT;

EID: 84956637137     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12843     Document Type: Article

References (28)

1. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP,. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta-analysis. BMJ Open 2013; 3: E001986.
2. Jensen MT, Marott JL, Allin KH, Nordestgaard BG, Jensen GB,. Resting heart rate is associated with cardiovascular and all-cause mortality after adjusting for inflammatory markers: The Copenhagen City Heart Study. Eur J Prev Cardiol 2012; 19: 102-8.
3. Bharucha AE, Charkoudian N, Andrews CN, Camilleri M, Sletten D, Zinsmeister AR, Low PA,. Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol 2008; 295: R874-80.
4. Mendis B, Simpson E, MacDonald I, Mansell P,. Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br J Clin Pharmacol 2012; 74: 437-44.
5. Gardiner SM, March JE, Kemp PA, Bennett T,. Effects of nitric oxide synthase inhibition with or without cyclooxygenase-2 inhibition on resting haemodynamics and responses to exendin-4. Br J Pharmacol 2006; 149: 802-9.
6. Smits MM, Muskiet MHA, Tonneijck L, Kramer MHH, Diamant M, van Raalte DH, Serné EH,. GLP-1 receptor agonist exenatide increases capillary perfusion independent of nitric oxide in healthy overweight men. Arterioscler Thromb Vasc Biol 2015; 35: 1538-43.
7. Valensi P, Chiheb S, Fysekidis M,. Insulin- A nd glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: Why they matter. Diabetologia 2013; 56: 1196-200.
8. Heart rate variability: Standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996; 93: 1043-65.
9. Berkelaar M, Eekhoff EMW, Simonis-Bik AMC, Boomsma DI, Diamant M, Ijzerman RG, Dekker JM, 't Hart LM, de Geus EJC,. Effects of induced hyperinsulinaemia with and without hyperglycaemia on measures of cardiac vagal control. Diabetologia 2013; 56: 1436-43.
10. Asmar A, Simonsen L, Asmar M, Madsbad S, Holst JJ, Frandsen E, Moro C, Jonassen T, Bülow J,. Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. Am J Physiol Endocrinol Metab 2015; 308: E641-9.
11. Meier JJ, Rosenstock J, Hincelin-Méry A, Roy-Duval C, Delfolie A, Coester H-V, Menge BA, Forst T, Kapitza C,. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: A randomized, open-label trial. Diabetes Care 2015; 38: 1263-73.
12. Hozawa A, Ohkubo T, Kikuya M, Ugajin T, Yamaguchi J, Asayama K, Metoki H, Ohmori K, Hoshi H, Hashimoto J, Satoh H, Tsuji I, Imai Y,. Prognostic value of home heart rate for cardiovascular mortality in the general population: The ohasama study. Am J Hypertens 2004; 17: 1005-10.
13. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC,. ELIXA Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015; 373: 2247-57.
14. Meier JJ,. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728-42.
15. Pyke C, Heller RS, Kirk RK, Orskov C, Reedtz-Runge S, Kaastrup P, Hvelplund A, Bardram L, Calatayud D, Knudsen LB,. GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014; 155: 1280-90.
16. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK,. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002; 110: 43-52.
17. Suzuki E, Yoshimura T, Omura Y, Sakaguchi M, Nishio Y, Maegawa H, Hisatomi A, Fujimoto K, Takeda J, Kashiwagi A,. Higher arterial stiffness, greater peripheral vascular resistance and lower blood flow in lower-leg arteries are associated with long-term hyperglycaemia in type 2 diabetic patients with normal ankle-brachial index. Diabetes Metab Res Rev 2009; 25: 363-9.
18. Dijkhorst-Oei LT, Boer P, Rabelink TJ, Koomans HA,. Nitric oxide synthesis inhibition does not impair water immersion-induced renal vasodilation in humans. J Am Soc Nephrol 2000; 11: 1293-302.
19. Sprangers F, Jellema WT, Lopuhaä CE, Endert E, Ackermans MT, Van Lieshout JJ, Van Der Zee JS, Romijn JA, Sauerwein HP,. Partial inhibition of nitric oxide synthesis in vivo does not inhibit glucose production in man. Metabolism 2002; 51: 57-64.
20. Trahair LG, Horowitz M, Hausken T, Feinle-Bisset C, Rayner CK, Jones KL,. Effects of exogenous glucagon-like peptide-1 on the blood pressure, heart rate, mesenteric blood flow and glycemic responses to intraduodenal glucose in healthy older subjects. J Clin Endocrinol Metab 2014; 99: E2628-34
21. Sheikh A,. Direct cardiovascular effects of glucagon like peptide-1. Diabetol Metab Syndr 2013; 5: 47.
22. Tonneijck L, Muskiet MHA, Smits MM, van Raalte DH, Diamant M,. Combining incretin-based drugs and RAAS inhibitors: More cons than pros? Lancet Diabetes Endocrinol 2014; 2: 684-5.
23. Muskiet MHA, Smits MM, Morsink LM, Diamant M,. The gut-renal axis: Do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol 2014; 10: 88-103.
24. Bogert LWJ, Wesseling KH, Schraa O, Van Lieshout EJ, de Mol BAJM, van Goudoever J, Westerhof BE, van Lieshout JJ,. Pulse contour cardiac output derived from non-invasive arterial pressure in cardiovascular disease. Anaesthesia 2010; 65: 1119-25.
25. Eeftinck Schattenkerk DW, van Lieshout JJ, van den Meiracker AH, Wesseling KR, Blanc S, Wieling W, van Montfrans GA, Settels JJ, Wesseling KH, Westerhof BE,. Nexfin noninvasive continuous blood pressure validated against Riva-Rocci/Korotkoff. Am J Hypertens 2009; 22: 378-83.
26. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JPH,. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373: 11-22.
27. Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, Fineman MS, Kim DD, Nauck MA,. Exenatide augments first- A nd second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 5991-7.
28. Calara F, Taylor K, Han J, Zabala E, Carr EM, Wintle M, Fineman M,. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther 2005; 27: 210-5.